RxSight, Inc. (NASDAQ:RXST) Insider Eric Weinberg Sells 10,000 Shares

RxSight, Inc. (NASDAQ:RXSTGet Free Report) insider Eric Weinberg sold 10,000 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $50.00, for a total value of $500,000.00. Following the completion of the sale, the insider now directly owns 299,978 shares in the company, valued at approximately $14,998,900. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Eric Weinberg also recently made the following trade(s):

  • On Monday, January 22nd, Eric Weinberg sold 10,000 shares of RxSight stock. The shares were sold at an average price of $48.00, for a total value of $480,000.00.
  • On Monday, January 8th, Eric Weinberg sold 10,000 shares of RxSight stock. The shares were sold at an average price of $42.00, for a total value of $420,000.00.
  • On Friday, December 22nd, Eric Weinberg sold 1,285 shares of RxSight stock. The shares were sold at an average price of $40.00, for a total value of $51,400.00.
  • On Friday, December 15th, Eric Weinberg sold 8,715 shares of RxSight stock. The shares were sold at an average price of $40.01, for a total value of $348,687.15.

RxSight Stock Performance

Shares of RXST stock opened at $47.24 on Friday. The firm has a market cap of $1.69 billion, a P/E ratio of -27.31 and a beta of 1.21. RxSight, Inc. has a fifty-two week low of $12.21 and a fifty-two week high of $50.20. The business’s 50 day moving average price is $40.44 and its 200-day moving average price is $32.20.

RxSight (NASDAQ:RXSTGet Free Report) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.07. The firm had revenue of $22.20 million for the quarter, compared to analyst estimates of $20.81 million. RxSight had a negative return on equity of 39.77% and a negative net margin of 71.87%. As a group, equities analysts predict that RxSight, Inc. will post -1.53 EPS for the current year.

Institutional Investors Weigh In On RxSight

Large investors have recently made changes to their positions in the business. RiverPark Advisors LLC grew its position in shares of RxSight by 70.0% in the 4th quarter. RiverPark Advisors LLC now owns 668 shares of the company’s stock worth $27,000 after buying an additional 275 shares during the last quarter. BluePath Capital Management LLC bought a new stake in shares of RxSight during the third quarter valued at approximately $32,000. Lazard Asset Management LLC bought a new stake in shares of RxSight during the second quarter valued at approximately $70,000. Tower Research Capital LLC TRC boosted its position in shares of RxSight by 788.0% during the third quarter. Tower Research Capital LLC TRC now owns 3,046 shares of the company’s stock valued at $85,000 after purchasing an additional 2,703 shares in the last quarter. Finally, IFP Advisors Inc bought a new stake in shares of RxSight during the second quarter valued at approximately $62,000. 66.51% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Needham & Company LLC raised their price objective on RxSight from $35.00 to $41.00 and gave the company a “buy” rating in a report on Monday, January 8th. Oppenheimer raised their price objective on RxSight from $50.00 to $54.00 and gave the company an “outperform” rating in a report on Monday, January 29th. Wells Fargo & Company raised RxSight from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $31.00 to $42.00 in a report on Wednesday, December 13th. Stifel Nicolaus assumed coverage on RxSight in a research report on Tuesday, December 12th. They set a “buy” rating and a $40.00 price target on the stock. Finally, Morgan Stanley assumed coverage on RxSight in a research report on Monday, December 4th. They set an “overweight” rating and a $36.00 price target on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $37.63.

View Our Latest Analysis on RXST

About RxSight

(Get Free Report)

RxSight, Inc, an ophthalmic medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.

Recommended Stories

Insider Buying and Selling by Quarter for RxSight (NASDAQ:RXST)

Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.